Catherine McNeal
Internal Medicine · Temple, TXNPI 1356302368
Payments from drug & device makers
Across 102 payments — averaging $1831.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$181K
- Novartis$4K
- Medicure Pharma Inc.$600
- Amarin Pharma, Inc.$240
- Sanofi-aventis U.S. LLC$224
- Dexcom, Inc.$130
- plus $325 from 3 others
Across 1 payment — averaging $5421.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
What the payments were for
- Consulting fees$18,71810%
- Speaking & faculty fees$149,88880%
- Travel & lodging$14,3568%
- Food & beverage$3,8502%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 89 | $180,860 |
| Novartis | 2 | $4,463 |
| Medicure Pharma Inc. | 2 | $600 |
| Amarin Pharma, Inc. | 3 | $240 |
| Sanofi-aventis U.S. LLC | 2 | $224 |
| Dexcom, Inc. | 1 | $130 |
| Esperion Therapeutics, Inc. | 1 | $121 |
| Boehringer Ingelheim | 1 | $106 |
| Janssen Scientific Affairs, LLC | 1 | $98 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$152,044
- RYBELSUS$27,859
- PELACARSEN$4,463
- ZYPITAMAG (pitavastatin)$600
- Vascepa$224
- DEXCOM G6 TRANSMITTER$130
- DISEASE STATE$125
- NEXLIZET$121
- NEXLETOL$121
- JARDIANCE$106
How this compares
$186,844 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 30 | $44,173 |
| JardianceEmpagliflozin | 18 | $31,691 |
| Rosuvastatin Calcium | 52 | $1,417 |
| Ezetimibe | 69 | $1,327 |
| Pioglitazone Hcl | 44 | $1,175 |
| Atorvastatin Calcium | 39 | $1,003 |
| ClopidogrelClopidogrel Bisulfate | 13 | $204 |
| Losartan Potassium | 11 | $200 |
| Metformin Hcl | 12 | $184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $180,860 | $44,17330 claims |
| Boehringer IngelheimJardiance | $106 | $31,69118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Temple
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.